ANGLE is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics. ANGLE's lead product is the Parsortix cell separation system, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is fewer than one CTC per billion healthy cells.
The Parsorter PR1, which has been launched as an instrumentation product for the research market, utilises ANGLE’s Parsortix microfluidic cell separation technology for the isolation of rare cells from whole blood samples. The system is based on a simple blood test and can be configured either for the counting and identification of CTCs in the blood or for the capture and recovery of CTCs as a liquid biopsy for molecular analysis of the cells. Potential research customers are major cancer research centres investigating the development of cancer and pharmaceutical companies developing new cancer drugs. The system is already in use in a number of leading centres, including the Paterson Institute for Cancer Research and the University of Surrey’s Oncology Department. The Parsortix system offers the prospect of personalised medicine with drugs and other treatment selected specifically to address the individual patient’s own cancer with better patient outcomes and lower costs of treatment.
“This project drew on many areas of eg’s expertise – fluidics, software development, mechanical engineering, industrial design, compliance and transfer to manufacture. It was great to work on an instrument that will enable what is a breakthrough technology in the area of cancer diagnostics. The Parsortix technology has the potential to transform the way cancer is diagnosed and treated which is very exciting,” said eg Director Andrew Ede.
Andrew Newland, CEO of ANGLE plc, said: “eg’s work was instrumental in automating the Parsortix system so that patient blood can be processed efficiently using ANGLE’s patented Parsortix technology to capture CTCs. This was a major step forward in bringing the Parsortix technology to market.”
eg technology is one of the UK’s growing product design, development and engineering consultancies, which is already a leading force in the medical, biotech and consumer sectors. Based at the heart of the Cambridge technology cluster, eg takes a dynamic yet practical approach, combining innovation and experience to quickly and cost-effectively deliver results to their clients.
About eg technology Ltd:
eg technology is one of the UK’s leading product design, development and engineering consultancies, working in the medical, biotech and consumer sectors. Whether we are working with a small biotechnology start-up or an industry-leading blue-chip, our clients receive a level of service that forms the foundation for a long-term relationship. Based at the heart of the Cambridge technology cluster, we work with companies worldwide to develop engineering solutions to specific product needs. We don’t simply “solve problems” – our experience ensures that we solve the right problems, managing risks and reducing time to market.
About ANGLE Plc Ltd:
ANGLE plc is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. ANGLE is listed on the London Stock Exchange AIM market (AGL.L).
ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE has launched a product for the research market and is aiming to secure CE Mark regulatory approval for the clinical market in 2013 with FDA approval in 2014.
*******
Press contact:
Caitlin Boast, Marketing Co-ordinator
Email: caitlin@egtechnology.co.uk
Tel: 01223 710799 or 07584 426607
________________________________________________